Loading…
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $20.6B | $3.8B | $2.1B | $1.5B | 20.1% | 4.8% | 4.6% |
| 2024 | $19.7B | $3.7B | $2.0B | $1.6B | 23.6% | 0.6% | 27.1% |
| 2023 | $19.6B | $3.5B | $1.6B | $1.7B | 22.0% | 6.6% | -18.2% |
| 2022 | $18.3B | $3.2B | $1.9B | $1.8B | 20.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 18,341 | 19,552 | 19,672 | 20,625 |
| Operating Revenue | - | 18,341 | 19,552 | 19,672 | 20,625 |
| Cost Of Revenue | - | 11,162 | 11,630 | 11,467 | 12,378 |
| Gross Profit | - | 7,179 | 7,922 | 8,205 | 8,247 |
| Operating Expense | - | 4,657 | 5,487 | 5,580 | 5,485 |
| Research And Development | - | 1,026 | 1,205 | 1,311 | 1,260 |
| Selling General And Administration | - | 3,631 | 4,282 | 4,269 | 4,225 |
| Total Expenses | - | 15,819 | 17,117 | 17,047 | 17,863 |
| Operating Income | - | 2,522 | 2,435 | 2,625 | 2,762 |
| Total Operating Income As Reported | - | 2,522 | 2,435 | 2,625 | 2,763 |
| EBITDA | - | 3,231 | 3,513 | 3,666 | 3,786 |
| Normalized EBITDA | - | 3,231 | 3,513 | 3,666 | 3,689 |
| EBIT | - | 2,598 | 2,903 | 3,086 | 3,208 |
| Interest Income | 34 | - | 26 | - | 41 |
| Interest Expense | - | 86 | 542 | 505 | 440 |
| Net Interest Income | - | -86 | -516 | -505 | -399 |
| Other Non Operating Income Expenses | - | 63 | 431 | 454 | 304 |
| Other Income Expense | - | 76 | 442 | 462 | 404 |
| Interest Income Non Operating | 34 | - | 26 | - | 41 |
| Interest Expense Non Operating | - | 86 | 542 | 505 | 440 |
| Net Non Operating Interest Income Expense | - | -86 | -516 | -505 | -399 |
| Pretax Income | - | 2,512 | 2,361 | 2,581 | 2,768 |
| Tax Provision | - | 563 | 743 | 531 | 614 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 21.52 |
| Net Income Continuous Operations | - | 1,949 | 1,618 | 2,050 | 2,154 |
| Net Income From Continuing And Discontinued Operation | - | 1,916 | 1,568 | 1,993 | 2,084 |
| Net Income From Continuing Operation Net Minority Interest | - | 1,898 | 1,572 | 1,993 | 2,084 |
| Net Income | - | 1,916 | 1,568 | 1,993 | 2,084 |
| Net Income Common Stockholders | - | 1,916 | 1,385 | 1,993 | 2,084 |
| Net Income Including Noncontrolling Interests | - | 1,967 | 1,614 | 2,050 | 2,154 |
| Normalized Income | - | 1,898 | 1,572 | 1,993 | 2,008.52 |
| Diluted NI Availto Com Stockholders | - | 1,916 | 1,385 | 1,993 | 2,084 |
| Basic Average Shares | - | 413.82 | 455 | 456 | 456 |
| Diluted Average Shares | - | 413.82 | 458 | 459 | 458 |
| Reconciled Depreciation | - | 633 | 610 | 580 | 578 |
| Reconciled Cost Of Revenue | - | 11,162 | 11,630 | 11,467 | 12,378 |
| Total Unusual Items | - | - | - | - | 97 |
| Total Unusual Items Excluding Goodwill | - | - | - | - | 97 |
| Preferred Stock Dividends | - | - | 183 | - | - |
| Minority Interests | - | -51 | -46 | -57 | -70 |
| Net Income Discontinuous Operations | - | 18 | -4 | 0 | 0 |
| Gain On Sale Of Security | - | - | - | - | 97 |
| Earnings From Equity Interest | - | 13 | 11 | 8 | 3 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| GE HealthCare Technologies Inc.this co. | GEHC | $29.0B | 13.93↓ discount | 2.80 | 20.1% | 9.24 |
| Zoetis Inc. | ZTS | $33.3B | 12.47 | 10.01 | 80.2% | 9.90 |
| IQVIA Holdings Inc. | IQV | $31.2B | 22.93 | 4.80 | 20.9% | 13.04 |
| Centene Corporation | CNC | $31.0B | -4.64 | 1.55 | -33.4% | -6.54 |
| Biogen Inc. | BIIB | $29.0B |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| 22.43 |
| 1.59 |
| 7.1% |
| 12.51 |
| ResMed Inc. | RMD | $28.2B | 20.12 | 4.72 | 23.5% | 14.47 |
| DexCom, Inc. | DXCM | $28.0B | 33.49 | 10.20 | 30.5% | 20.97 |
| Mettler-Toledo International Inc. | MTD | $23.9B | 27.44 | - | -3676.8% | 20.87 |
| Insmed Incorporated | INSM | $22.7B | -17.81 | 30.77 | -172.8% | - |
| Peer Median | - | 21.28 | 4.80 | 14.0% | 13.04 | |